Fuse Science Inc (DROP)

[JPD3]

Good question... My guess is that the new guy will have a significant role to play:

http://ir.stockpr.com/fusescience/board-of-directors

R. Douglas Armstrong, Ph.D., has over 25 years of life science industry business and finance experience, with emphasis on early stage and emerging growth life science companies. Dr. Armstrong is a seasoned and diverse life science operational and banking executive, who served as the CEO of TyraTech from December 2006 to early 2010 and the CEO of Aastrom Biosciences (where he was also Chairman) from 1991 to 2006, leading both through initial public offerings. He specializes in development and implementation of capital strategies having personally led over $300 million in capital raises through a variety of public, PIPE and other structured deals, including strategic partnering transactions. Since July 2011, Dr. Armstrong has served as a member of the senior management of Tekesta Capital Partners, a division of WestPark Capital, Inc., and since 2010, as a founding partner and President of Auxol Capital, LLC, a life science investment fund. From February 2010 to July 2011, Dr. Douglas served as Senior Managing Director of Corporate Finance for LifeTech Capital, a division of Aurora Capital, LLC. Dr. Armstrong also served as a staff scientist for The Burnham Institute (La Jolla Cancer Research Institute) from 1987 to 1991, and as Assistant Professor, Department of Pharmacology and Cancer Research Institute at the University of California from 1983 to 1987. Dr. Armstrong holds a Ph.D. degree in Pharmacology from the Medical College of Virginia and a BA degree in Chemistry from the University of Richmond.

Tekesta Capital Partners: http://www.wpcapital.com/tekesta.html

Auxol Capital, LLC: http://www.onemedplace.com/network/list/cid/15027/

Between the two sources above, I would say that Fuse is well positioned for additional capital at more favorable terms than their current source (National Securities Corp: http://www.NationalSecurities.com/)